[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fu Jen Catholic University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":195},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,42,75,97,123,143,169],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100627944","multidimensional-correlation-analysis-of-heart-rate-variability-and-weaning-assessment-parameters-in-critically-mechanically-ventilated-patients-100627944",false,"NCT07455214","Multidimensional Correlation Analysis of Heart Rate Variability and Weaning Assessment Parameters in Critically Mechanically Ventilated Patients","Inclusion Criteria:\n\n* Age between 18 and 85 years.\n* Received mechanical ventilation for more than 24 hours and clinically assessed as ready for a Spontaneous Breathing Trial (SBT).\n* Stable ECG signal quality before extubation, meeting the basic requirements for HRV analysis.\n* Obtained informed consent from the patient or their legal representative, and agreed to participate in this study and cooperate with the 72-hour follow-up after extubation.\n\nExclusion Criteria:\n\n* Individuals with permanent pacemakers, defibrillators, or other devices that affect monitoring data.\n* Individuals on continuous deep sedation (RAS ≤ -4) and unable to regain consciousness in the short term.\n* Individuals with severe arrhythmias or unstable cardiovascular conditions that prevent reliable HRV analysis.\n* Individuals with cognitive impairment or mental illness that prevents them from cooperating with the research process, or individuals deemed unsuitable for participation in this study by their clinicians.","ALL","18 Years","85 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","Background： Conventional weaning assessments are widely used but often affected by factors such as poor patient cooperation, neuromuscular issues, or unstable consciousness, leading to uncertainty in extubation timing. Studies have shown that HRV differs significantly between successful and failed extubation cases. However, most research features small sample sizes, focuses on single HRV indicators, and lacks integration with traditional assessments, limiting HRV's clinical application.\n\nEffect： The study aims to develop a predictive model combining HRV and traditional weaning indicators to provide a more objective and sensitive physiological reference for ventilator weaning decisions in critical care settings.",[24],"Weaning Invasive Mechanical Ventilation",[26,27,28],"Heart rate variability","BEATINFO ECG Sensor","Weaning assessment parameters","RECRUITING","2026-04-06",{"date":32,"type":33},"2026-04-09","ACTUAL",{"date":35,"type":33},"2025-12-09",{"date":37,"type":20},"2026-08-31",{"name":39,"class":40},"Fu Jen Catholic University Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":62,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100623725","impact-of-a-probiotic-supplementation-with-lifestyle-modification-on-liver-steatosis-fibrosis-and-metabolic-health-in-patients-with-metabolic-dysfunction-associated-steatotic-liver-disease-masld-100623725","NCT07400367","Impact of a Probiotic Supplementation With Lifestyle Modification on Liver Steatosis, Fibrosis, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","Impact of a Multi-strain Probiotic Supplementation With Lifestyle Modification on Liver Steatosis, Fibrosis, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","Inclusion Criteria:\n\n* ALT ≥ 60 U\u002FL\n* Liver steatosis identified by ultrasound\n* Meet at least one cardiometabolic criteria:\n\n  1. BMI ≥ 25 kg\u002Fm2 (Asian ≥23)\n  2. Waist circumference: \\> 94cm (M) 80cm(F)\n  3. Fasting blood glucose ≥ 100 mg\u002FdL\n  4. HbA1c ≥ 5.7\n  5. Receiving treatment of diabetes\n  6. Receiving treatment of Hypertension\n  7. Average home blood pressure: ≥ 130\u002F85 mmHg\n  8. TG ≥ 150 mg\u002FdL\n  9. HDL ≤ 40 mg\u002FdL\n  10. Receiving treatment of dyslipidemia\n\nExclusion Criteria:\n\n* HBsAg(+)\n* Anti-HCV (+)\n* Cirrhosis\n* Excessive alcohol intake ( Male over 210g\u002Fwk; Female over 140mg\u002Fwk)\n* Could not rule out Autoimmune hepatitis (ANA, or AMA or ASMA (+))\n* Could not rule out drug related hepatitis\n* Receiving drug that might induce liver steatosis:\n* Glucocorticoids\n* Amiodarone\n* Tamoxifen\n* Methotrexate\n* Valproate\n* Tetracycline\n* Chemotherapeutic agents\n* Receiving immune modulators or biologics\n* Receiving antibiotics within 1 month\n* Receiving any cancer treatment\n* Have diagnosis of \"Catastrophic Illness\" defined by Health Administration of Taiwan\n* eGFR\\\u003C60\n* Pregnancy\n* Currently enrolled in other dietary or pharmacology clinical trial","80 Years",{"count":51,"type":20},80,"INTERVENTIONAL",[54],"NA","Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the new clinical term introduced in 2023 to redefine what was formerly known as Non-Alcoholic Fatty Liver Disease (NAFLD). It is defined as fatty liver confirmed by imaging or biopsy, accompanied by at least one cardiometabolic risk factor (e.g., hyperglycemia, dyslipidemia, hypertension, or obesity). Its pathological progression ranges from simple steatosis to steatohepatitis, primarily driven by excessive energy intake, hepatic lipid accumulation, and insulin resistance.\n\nMASLD is currently the most prevalent chronic liver disease globally, with a prevalence rate of approximately 30-40%. However, there is no satisfactory pharmacological treatment, leaving lifestyle modification as the primary therapeutic approach. Many patients struggle to effectively adjust their habits, leading to persistent hepatic inflammation and damage, which may eventually progress to end-stage diseases such as cirrhosis and hepatocellular carcinoma. In many developed countries, MASLD has become the leading indication for liver transplantation, imposing a heavy burden on healthcare systems.\n\nGut dysbiosis is closely linked to MASLD. An imbalance in the gut microbiota disrupts the gut-liver axis, leading to impaired intestinal mucosal barrier function. This allows bacterial components to enter the circulation, further triggering hepatic inflammation and abnormal lipid metabolism. Consequently, modulating the gut microbiota is considered a potential therapeutic strategy.\n\nOver the past decade, probiotics, prebiotics, and synbiotics have been extensively studied as non-pharmacological treatments for NAFLD. Multiple studies indicate that these products can reduce liver enzymes (AST, ALT), insulin resistance (HOMA-IR), and inflammatory markers (hs-CRP, TNF-α). The most effective combinations typically involve Lactobacillus, Bifidobacterium, and Streptococcus, with a recommended duration of approximately 12 weeks. However, the impact of these products on liver fibrosis, hepatic fat accumulation, and cardiometabolic risk factors remains inconclusive.\n\nThe probiotic product to be tested consists of Lactobacillus salivarius AP-32, Lactobacillus rhamnosus bv-77, Bifidobacterium animalis CP-9, and Lactobacillus reuteri GL-104. This formulation complies with food safety regulations. In clinical studies, it had been proven as an effective adjuvant method that increased beneficial gut bacteria such as Akkermansia muciniphila and improved the control of blood glucose, lipids, and inflammatory markers.\n\nStudy Objectives\n\nThis study aims to investigate the efficacy of this probiotic product as an adjuvant therapy alongside lifestyle modifications in adult patients with MASLD. We will evaluate its impact on:\n\n1. The degree of liver fibrosis and steatosis\n2. Cardiometabolic risk factors (BMI, waist circumference, blood lipids, and blood glucose).\n3. Inflammatory markers.\n4. Gut microbiota composition.",[57,58,59,60,61],"Liver Elastography","Liver Steatosis","Liver Function Test","Insulin Resistance","Cardiometabolic Risk Factors",[63,64,65,66],"MASLD","Probiotics","Liver fibrosis","Liver steatosis","2026-04-03",{"date":30,"type":33},{"date":70,"type":33},"2026-04-01",{"date":72,"type":20},"2027-08",{"name":39,"class":40},2,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":15,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":52,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":41},"100630897","multimedia-health-education-on-physical-fitness-and-physical-activity-for-patients-with-chronic-kidney-disease-100630897","NCT07493642","Multimedia Health Education on Physical Fitness and Physical Activity for Patients With Chronic Kidney Disease","Inclusion Criteria:\n\n* Conscious adults aged 20 years or older who are literate and able to communicate in Mandarin or Taiwanese.\n* Diagnosed with chronic kidney disease (CKD) stage 1 to 3b according to the CKD-EPI formula and confirmed by a nephrologist.\n* Able to operate a mobile device (such as a smartphone, tablet, or computer) and have access to equipment capable of playing multimedia videos; family members or caregivers may assist if necessary.\n* Able to view and understand multimedia educational video content.\n\nExclusion Criteria:\n\n* Individuals with cognitive or psychiatric disorders that prevent understanding or adherence to the exercise program.\n* Individuals with gait instability or limb amputation who are unable to perform the exercise protocol.\n* Individuals with poorly controlled cardiovascular disease, such as heart failure, myocardial infarction, angina, arrhythmia, or those who have experienced chest pain during activity or rest within the past three months.\n* Individuals deemed unsuitable for exercise by their attending physician.\n* Individuals with poorly controlled diabetes (HbA1C \\> 9%) accompanied by retinopathy or foot ulcers.","20 Years",{"count":83,"type":20},60,[54],"This clinical trial aims to determine whether a multimedia educational intervention can effectively improve physical fitness and physical activity levels in patients with chronic kidney disease (CKD), while also evaluating its overall outcomes.\n\nThe study primarily seeks to answer the following questions:\n\n* Can multimedia education enhance CKD patients' cardiorespiratory endurance, muscle strength, flexibility, and physical activity levels?\n* Do patients receiving multimedia education demonstrate greater improvements in health behavior and fitness compared to those receiving standard education alone?\n\nResearchers will compare a multimedia educational video program with conventional patient education to assess whether the multimedia approach helps patients maintain regular exercise and improve physical performance.\n\nParticipants will:\n\n* Be randomly assigned to either the multimedia education group or the standard education group.\n* Take part in a 12-week intervention and assessment period.\n* Undergo pre- and post-intervention evaluations, including:\n* Six-minute walk test, grip strength and chair-stand test, flexibility test, and body composition analysis (BMI, waist-to-hip ratio, InBody).\n* Completion of a physical activity questionnaire (IPAQ-C). The findings will be used to evaluate the clinical value of multimedia education in CKD management and to support the development of effective patient exercise education programs.",[87,88],"Chronic Kidney Disease (CKD)","CKD Stage 1-3","2026-03-23",{"date":91,"type":33},"2026-03-25",{"date":93,"type":33},"2025-11-17",{"date":95,"type":20},"2026-07-31",{"name":39,"class":40},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":52,"phases":104,"briefSummary":105,"conditions":106,"keywords":110,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":41},"100628260","the-use-of-remimazolam-versus-dexmedetomidine-for-patients-receiving-drug-induced-sleep-endoscopy-100628260","NCT07459322","The Use of Remimazolam Versus Dexmedetomidine for Patients Receiving Drug-Induced Sleep Endoscopy","Inclusion Criteria:\n\n* Patients age \\> 18 years old\n* American Society of Ansthesiologists functional class \\\u003C III\n* Schedule to receive DISE exam for evaluation of OSAS\n\nExclusion Criteria:\n\n* Patient refusal\n* Allergic to experimental medication\n* History of central nervous system diseases\n* History of psychiatric diseases\n* Pregnancy\n* Severe, uncontrolled systemic diseases",{"count":83,"type":20},[54],"This study seeks to compare the clinical efficacy and safety of the novel sedative Remimazolam with Dexmedetomidine in Drug-Induced Sleep Endoscopy (DISE), evaluating their performance in sedation depth stability, incidence of adverse events, and postoperative recovery time, thereby providing evidence-based guidance for sedative selection in OSA patients. Additionally, it aims to develop a model for predicting upper airway obstruction sites by analyzing Polysomnography (PSG) data with artificial intelligence, enhancing diagnostic accuracy and treatment decision-making efficiency for Obstructive Sleep Apnea (OSA) to optimize clinical management.",[107,108,109],"OSAS (Obstructive Sleep Apneas Syndrome)","DISE","Sedation",[111,108,109,112,113],"OSAS","Remimazolam","Dexmedetomidine","NOT_YET_RECRUITING","2026-03-04",{"date":117,"type":33},"2026-03-09",{"date":119,"type":20},"2026-04-15",{"date":121,"type":20},"2027-12-31",{"name":39,"class":40},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":49,"enrollmentInfo":130,"targetDuration":4,"studyType":52,"phases":132,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":140,"leadSponsor":142,"locationsCount":4},"100627945","ercp-management-in-mild-gallstone-induced-pancreatitis-patients-declining-subsequent-cholecystectomy--a-randomized-control-trial-100627945","NCT07455227","ERCP Management in Mild Gallstone-Induced Pancreatitis Patients Declining Subsequent Cholecystectomy : a Randomized Control Trial.","Comparison of Endoscopic Sphincterotomy and Conservative Management in Mild Gallstone-Induced Pancreatitis Patients Declining Subsequent Cholecystectomy : a Randomized Control Trial.","Inclusion Criteria:\n\n• Diagnosis of gallstone-related pancreatitis (classified as mild pancreatitis according to the 2012 revised Atlanta classification and definitions).\n\n• Imaging studies reveal the presence of gallstones or sludge, along with at least one of the following conditions: i. Imaging evidence of common bile duct dilation (common bile duct diameter \\> 8 mm for patients aged ≤ 75 years; \\> 10 mm for patients aged \\> 75 years).\n\nii. Biochemical evidence of cholestasis with total bilirubin levels between 1.8 - 4 mg\u002FdL.\n\niii. Alanine aminotransferase (ALT) levels greater than twice the upper limit of normal.\n\n\\-",{"count":131,"type":20},30,[54],"to investigate the role and potential benefits or drawbacks of ERCP with sphincterotomy in patients declining subsequent cholecystectomy for gallstone-induced pancreatitis.",[135],"Pancreatitis","2026-03-03",{"date":138,"type":33},"2026-03-06",{"date":70,"type":20},{"date":141,"type":20},"2028-05-01",{"name":39,"class":40},{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":149,"sex":150,"minAge":81,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":152,"conditions":153,"keywords":156,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":41},"100581626","development-of-biomarkers-for-monitoring-menopause-in-women-100581626","NCT06852755","Development of Biomarkers for Monitoring Menopause in Women","Inclusion Criteria:\n\n* Biological female, age order than 20 years old.\n\nExclusion Criteria:\n\n* Person with cancer.\n* Person with any known acute or chronic infection.\n* Person with known chronic illness under follow up or treatment.\n* Pregnancy, one year withing delivery, under breast feeding, or three months within breast feeding.\n* Under any female horemone therapy.",true,"FEMALE",{"count":19,"type":20},"This cross-sectional study aims to develop and validate mitochondrial biomarkers for monitoring menopause in women. The study will involve 100 participants divided into three groups: reproductive period, perimenopausal transition period, and postmenopausal period. Peripheral blood samples will be collected, and mitochondrial quality and quantity will be assessed using both qualitative and quantitative analyses. The study will identify potential biomarkers through metabolomics and validate them for monitoring the perimenopausal transition, providing a novel approach for women's health management during menopause.",[154,155],"Perimenopausal Biomarkers","Mitochondrial Biomarkers",[157,158,159,160],"Perimenopausal Transition","Mitochondria","Biomarker","Women's Health","2025-05-20",{"date":163,"type":33},"2025-05-25",{"date":165,"type":33},"2024-07-30",{"date":167,"type":20},"2026-08",{"name":39,"class":40},{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":52,"phases":179,"briefSummary":180,"conditions":181,"keywords":184,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":41},"100579724","foot-reflexology-for-chronic-low-back-pain-100579724","NCT06828016","Foot Reflexology for Chronic Low Back Pain","A Randomized Controlled Study of Foot Reflexology for the Management of Chronic Low Back Pain","Inclusion Criteria:\n\n* chronic low back pain for more than 12 weeks\n\nExclusion Criteria:\n\n* pregnancy, patients with comorbidities of major injuries or illnesses of National Health Insurance, patients diagnosed with major mental illness according to DSM-V criteria or under the care of mental health services, patients who have had adverse reactions to foot reflexology before, patients with recent surgery or vascular disease of lower extremities, patients who meet contraindications to foot reflexology.","100 Years",{"count":178,"type":20},90,[54],"The aim of this 2-year randomized, double-blinded clinical trial is to investigate the effect of 6 or 12 sessions of weekly 45-minute to 1-hour foot reflexology interventions on physical function and symptoms, pain, health-related quality of life, and ultrasonic shear wave elasticity of plantar fascia among chronic low back pain patients. The results of this study will explore the effect of foot reflexology intervention on physical function and symptoms, pain, health-related quality of life, and ultrasonic shear wave elasticity of plantar fascia among chronic low back pain patients. Our data will also provide relevant scientific evidence and insight into the utility of foot reflexology for the management of chronic low back pain.",[182,183],"Chronic Low Back Pain","Foot Reflexology",[185,186],"chronic low back pain","foot reflexology","2025-02-10",{"date":189,"type":33},"2025-02-14",{"date":191,"type":33},"2025-01-18",{"date":193,"type":20},"2027-12",{"name":39,"class":40},""]